In November 2025, the Pan American Health Organization confirmed something that would have seemed unthinkable a decade ago: the Americas — the first world region ever to eliminate measles — had lost that status, after Canada let a transmission chain run for more than twelve months [source: Pan American Health Organization, 2025]. Months earlier, the United States had recorded 2,289 confirmed measles cases in 2025, its worst year since 1992, including the deaths of two unvaccinated children in Texas and one adult in New Mexico — the first US measles deaths in a decade [source: US Centers for Disease Control and Prevention, 2026]. By late July 2026 the US count had already climbed past that, to 2,318 [source: US Centers for Disease Control and Prevention, 2026]. Across the Atlantic, the WHO European Region had logged 127,350 cases in 2024, its highest total in more than 25 years [source: WHO/Europe and UNICEF, 2025].
None of this is a mystery. Measles is one of the most contagious diseases known, and one of the most thoroughly vaccine-preventable. Its return is not a story about a new or mutating pathogen. It is a story about a threshold — the level of vaccination coverage that keeps the virus from spreading — and what happens when a community slips below it.
In this article
- Why measles is different: the math of contagion
- What the case data shows: measured, and modeled
- Why vaccination coverage slipped
- The autism myth versus the evidence
- What measles actually does to the body
- "Elimination" at risk: what the status means
- What would actually move the needle
- Conclusion: what to watch
Why measles is different: the math of contagion
To understand the resurgence, start with a single number. Epidemiologists estimate the basic reproduction number of measles — the average number of people one infected person would infect in a fully susceptible population — at roughly 12 to 18 [source: US Centers for Disease Control and Prevention, 2025]. For comparison, seasonal influenza sits near 1 to 2. Measles spreads through the air and lingers: the virus can hang in a room for up to two hours after an infected person has left, and at least 90% of non-immune people exposed to it will catch it [source: US Centers for Disease Control and Prevention, 2025].
That extreme contagiousness is exactly why coverage has to be so high. To stop measles from spreading, a community needs roughly 95% of its members immune, with two doses of the measles-mumps-rubella (MMR) vaccine — a bar higher than for almost any other disease. This is the logic of herd immunity: when enough people are protected, the virus cannot find a chain of susceptible hosts, and even the unvaccinated — newborns too young for the shot, people with weakened immune systems — are shielded.
The relationship between coverage and outbreaks is causal, not coincidental, and it follows directly from that reproduction number. When two-dose coverage falls below about 95%, the effective transmission rate climbs above one, and a single imported case can seed a self-sustaining outbreak. One important caveat keeps this honest: outbreaks track local pockets of low coverage, not national averages. A country can post a reassuring headline figure while a specific county, school, or tight-knit community sits far below the line — and that is precisely where measles returns.
What the case data shows: measured, and modeled
It is worth separating two kinds of numbers that often get blurred in coverage of measles: cases that surveillance systems actually confirm, and totals that statistical models estimate.
The confirmed counts are stark on their own. In the United States, the Centers for Disease Control and Prevention tallied 2,289 confirmed cases across 2025 — the most since 1992 — with 48 outbreaks and 90% of cases linked to those outbreaks [source: US Centers for Disease Control and Prevention, 2026]. The center of gravity was a West Texas outbreak that began in January 2025 in a Mennonite community in Gaines County, where about one in five kindergartners held a vaccine exemption against a state average below 4% [source: US Centers for Disease Control and Prevention, 2025]. For scale, the previous post-elimination record was 1,274 cases in 2019 [source: US Centers for Disease Control and Prevention, 2025]. In the WHO European Region, the 127,350 cases confirmed in 2024 were double the 2023 figure and the highest since 1997; children under five made up more than 40% of them, and over half of all patients were hospitalized [source: WHO/Europe and UNICEF, 2025].
The global figure is different in kind. The WHO and CDC jointly estimated 10.3 million measles cases worldwide in 2023 — up about 20% from 2022 — and roughly 107,500 deaths, most of them children under five [source: World Health Organization, 2024]. That 10.3 million is a modeled estimate built to account for the vast under-reporting in places with weak surveillance, not a direct count. Both kinds of number matter, but they answer different questions, and it is worth knowing which one you are reading. When a headline says a country had its "worst year since" some date, that claim is scoped to a specific record — post-1992 for US confirmed cases, post-1997 for the European Region — not to all of history.
Why vaccination coverage slipped
If the vaccine works and the math is clear, why did coverage fall? The honest answer is that several forces pushed in the same direction, and understanding them matters more than assigning blame.
The first was the pandemic. COVID-19 disrupted routine childhood immunization worldwide in 2020 and 2021, and many countries have not fully recovered. Globally, an estimated 83% of children received a first dose of measles vaccine in 2023 and only 74% the recommended second dose — well short of the 95% needed — leaving more than 22 million children who missed their first dose that year [source: World Health Organization, 2024]. In the United States, MMR coverage among kindergartners fell to 92.5% in the 2024–25 school year, the fourth straight year below the 95% target, while vaccine exemptions rose to a record 3.6% [source: US Centers for Disease Control and Prevention, 2025].
The second is a cluster of harder-to-measure factors: gaps in access and health systems, growing vaccine hesitancy, and misinformation. It is easy to caricature parents who delay or decline vaccines, but the reasons are varied and worth stating fairly. Some face practical barriers — cost, time, distance from a clinic. Some belong to communities with long-standing distrust of public institutions. Some have absorbed false claims online. Distinguishing these is not an academic exercise: a family kept away by a clinic's hours needs a different response than one persuaded by a myth. What the evidence does not support is treating hesitancy as though it rested on genuine scientific doubt about the vaccine's safety. On the central question that drives much of that doubt, the science is not open.
The autism myth versus the evidence
The most damaging myth about the MMR vaccine — that it causes autism — deserves to be addressed directly, because fairness to hesitant parents does not mean pretending the question is unsettled. It is settled.
The claim traces to a 1998 paper by Andrew Wakefield in The Lancet. That paper was retracted in 2010 after investigations found it was based on manipulated data and undisclosed conflicts of interest, and Wakefield lost his medical license. In the years since, some of the largest studies in epidemiology have looked for any link and found none. The most powerful is a Danish nationwide cohort that followed 657,461 children born between 1999 and 2010: MMR vaccination was not associated with autism, did not trigger it in children with other risk factors, and produced no clustering of diagnoses after the shot [source: Annals of Internal Medicine, 2019].
This is the place where the layering between a claim and a verified fact matters most. Reporting that both-sides a settled scientific question does real harm here, because it manufactures a debate the evidence has already closed. Explaining why some parents believe the myth is worthwhile; presenting the myth itself as an open scientific controversy is not.
What measles actually does to the body
Part of why measles faded from public fear is that most people alive today have never seen it. It is worth recalling what the disease does, on the evidence, without exaggeration.
Among unvaccinated Americans who catch measles, about one in five is hospitalized [source: US Centers for Disease Control and Prevention, 2025]. As many as one in twenty children develops pneumonia, the most common cause of measles death in the young; about one in a thousand develops encephalitis, a swelling of the brain that can cause lasting disability; and between one and three of every thousand infected children die of respiratory or neurological complications [source: US Centers for Disease Control and Prevention, 2025]. A rare and always-fatal complication, subacute sclerosing panencephalitis, can emerge seven to ten years after an apparent recovery [source: US Centers for Disease Control and Prevention, 2025].
There is also a subtler harm that researchers only recently pinned down. Studies published in Science and Science Immunology in 2019 showed that measles can cause "immune amnesia": the infection wipes out part of the immune system's memory of past pathogens. In one study, children lost between 11% and 73% of their protective antibodies after a bout of measles, leaving them vulnerable for years to infections they had already beaten once [source: Science, 2019]. In other words, measles does not just cause one dangerous illness — it can quietly erase protection the body spent years building.
"Elimination" at risk: what the status means
"Elimination" is a technical term, and it is easy to misread. It does not mean a disease has been eradicated forever; it means a region has recorded no continuous, homegrown transmission chain lasting twelve months or longer, a status that regional commissions formally verify and can withdraw [source: Pan American Health Organization, 2025]. The United States has held it since 2000.
That status is now genuinely in question. On 10 November 2025, PAHO confirmed that Canada had lost its elimination status after an outbreak that began in New Brunswick in October 2024 crossed the twelve-month line, with more than 5,200 cases [source: Pan American Health Organization, 2025]. Because a single country losing the status pulls down its whole region, the Americas — verified measles-free again only in 2024 — lost that region-wide standing as well [source: Pan American Health Organization, 2025]. The United States kept its country-level status at that review, but the West Texas chain that started in January 2025 is the open question: if it cannot be shown to have been interrupted within twelve months, the US could lose a status it has held for a quarter century [source: Pan American Health Organization, 2026]. This is a formal epidemiological determination, not a rhetorical flourish — which is what makes it a useful, verifiable signal to watch.
What would actually move the needle
The uncomfortable and hopeful fact about measles is that the world already has the tool it needs. The MMR vaccine is inexpensive, safe, and about 97% effective after two doses. The constraint is not a missing technology but sustained coverage.
The public-health playbook is unglamorous and well understood. Restore routine two-dose MMR coverage to at least 95% in every community, not just on average. Run catch-up campaigns to reach children who missed doses during the pandemic years. Strengthen surveillance so outbreaks are caught early, especially in regions that under-report. And counter misinformation not by lecturing but through clear, trusted, local communication — often from clinicians and community figures people already know. The WHO, UNICEF, and vaccine-access partners have pressed all of these, but each depends on political will and steady funding rather than any new breakthrough [source: World Health Organization, 2024]. The Americas eliminated measles not once but twice, which is the strongest evidence that the goal is reachable when coverage holds [source: Pan American Health Organization, 2025].
Conclusion: what to watch
Measles is the rare public-health problem where the science is clear, the numbers are measurable, and the fix is known — and where the setback comes almost entirely from coverage slipping below a line the math has drawn for us. Over the next year, a few signals will tell the story. Whether the United States interrupts its West Texas–linked chain in time to keep its elimination status. Whether kindergarten vaccination rates stop falling and start climbing back toward 95%. Whether Europe's 2024 spike proves to be a peak or a plateau. And whether the countries with the thinnest coverage can close the gap before measles, one of the oldest diseases we know how to stop, settles back in for good. The virus has not changed. The open question is whether the protection around it will.